New strategy aims to boost addiction treatment and curb HIV in central asia

NCT ID NCT05579470

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a program to expand medication-assisted treatment for opioid addiction in Kazakhstan, Kyrgyzstan, and Tajikistan. Researchers will train local health officials and track how many people start and stay on treatment. The goal is to reduce HIV spread among people who inject drugs and their partners.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NIATx (a behavioral intervention to improve addiction treatment services)
What this could lead to: If successful, this could help more people with opioid addiction get effective treatment, reducing HIV transmission and improving health in Central Asia.
What could go wrong: This is an implementation study, not a test of a new drug. Success depends on local adoption and may not apply to other regions. Results are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Columbia University Global Health Research Center of Central Asia
RECRUITING

Almaty, Kazakhstan
Den Sooluk Nuru
RECRUITING

Bishkek, Kyrgyzstan
Institute for International Health and Education
RECRUITING

Dushanbe, Tajikistan
Yale University
ACTIVE_NOT_RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.